Kamila Naxerova, Ph.D. - Publications

Affiliations: 
2014 Biology: Medical Sciences, Division of Harvard University, Cambridge, MA, United States 
Area:
Genetics, Oncology

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, ... ... Naxerova K, et al. Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors. Nature Cancer. 5: 1681-1696. PMID 39406916 DOI: 10.1038/s43018-024-00840-y  0.301
2024 Wassenaar EC, Gorelick AN, Hung WT, Cheek DM, Kucukkose E, Lee IH, Blohmer M, Degner S, Giunta P, Wiezer RM, Raicu MG, Ubink I, Klaasen SJ, Lansu N, Watson EV, ... ... Naxerova K, et al. A unique interplay of access and selection shapes peritoneal metastasis evolution in colorectal cancer. Biorxiv : the Preprint Server For Biology. PMID 39386634 DOI: 10.1101/2024.09.25.614736  0.306
2023 Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, ... ... Naxerova K, et al. Germline mutations and developmental mosaicism underlying -mutant lung cancer. Medrxiv : the Preprint Server For Health Sciences. PMID 37808694 DOI: 10.1101/2023.09.28.23296274  0.305
2023 Datta M, Chatterjee S, Perez EM, Gritsch S, Roberge S, Duquette M, Chen IX, Naxerova K, Kumar AS, Ghosh M, Emblem KE, Ng MR, Ho WW, Kumar P, Krishnan S, et al. Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proceedings of the National Academy of Sciences of the United States of America. 120: e2219199120. PMID 36724255 DOI: 10.1073/pnas.2219199120  0.679
2022 Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Posada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, ... ... Naxerova K, et al. Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis. Nature Cancer. 2: 1243. PMID 35122065 DOI: 10.1038/s43018-021-00283-9  0.34
2021 Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Possada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, ... ... Naxerova K, et al. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. Nature Cancer. 2: 414-428. PMID 34179825 DOI: 10.1038/s43018-021-00183-y  0.405
2020 Chen IX, Newcomer K, Pauken KE, Juneja VR, Naxerova K, Wu MW, Pinter M, Sen DR, Singer M, Sharpe AH, Jain RK. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proceedings of the National Academy of Sciences of the United States of America. PMID 32907939 DOI: 10.1073/Pnas.2002806117  0.54
2020 Naxerova K. Defining the role of lymph node metastasis in systemic breast cancer evolution. Ebiomedicine. 57: 102852. PMID 32574957 DOI: 10.1016/J.Ebiom.2020.102852  0.312
2019 Heyde A, Reiter JG, Naxerova K, Nowak MA. Consecutive seeding and transfer of genetic diversity in metastasis. Proceedings of the National Academy of Sciences of the United States of America. PMID 31239334 DOI: 10.1073/Pnas.1819408116  0.425
2019 Chauhan VP, Chen IX, Tong R, Ng MR, Martin JD, Naxerova K, Wu MW, Huang P, Boucher Y, Kohane DS, Langer R, Jain RK. Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 31040208 DOI: 10.1073/Pnas.1819889116  0.685
2019 Talele NP, Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Michelakos T, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, et al. Abstract A115: Use of angiotensin system inhibitors is associated with immune activation and longer survival in pancreatic ductal adenocarcinoma patients Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A115  0.477
2019 Liu H, Ho WW, Naxerova K, Grahovac J, Nia H, Chen I, Posada JM, Schanne DH, Pinter M, Crain J, Qi X, Clark JW, Hong TS, Ryan DP, Huang P, et al. Abstract A18: Angiotensin receptor blockers normalize the pancreatic ductal adenocarcinoma stroma by reprogramming carcinoma-associated fibroblasts Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-A18  0.685
2019 Naxerova K. Tumor mutations are not alone in the plasma Science Translational Medicine. 11: eaaz9767. DOI: 10.1126/Scitranslmed.Aaz9767  0.344
2018 Sack LM, Davoli T, Li MZ, Li Y, Xu Q, Naxerova K, Wooten EC, Bernardi RJ, Martin TD, Chen T, Leng Y, Liang AC, Scorsone KA, Westbrook TF, Wong KK, et al. Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. Cell. PMID 29576454 DOI: 10.1016/J.Cell.2018.02.037  0.4
2018 Ng MR, Sabbatino F, Duquette M, Naxerova K, Badeaux M, Ferraro GB, Chin SM, Bezwada D, Brachtel EF, Ferrone S, Jain RK. Abstract LB-057: Hypoxia regulation of antigen presentation machinery expression in breast cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-Lb-057  0.432
2017 Naxerova K, Reiter JG, Brachtel E, Lennerz JK, van de Wetering M, Rowan A, Cai T, Clevers H, Swanton C, Nowak MA, Elledge SJ, Jain RK. Origins of lymphatic and distant metastases in human colorectal cancer. Science (New York, N.Y.). 357: 55-60. PMID 28684519 DOI: 10.1126/Science.Aai8515  0.477
2017 Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, et al. Use of Angiotensin System Inhibitors is Associated with Immune Activation and Longer Survival in Non-Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28600474 DOI: 10.1158/1078-0432.Ccr-17-0256  0.468
2017 Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, et al. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine. 9. PMID 28539475 DOI: 10.1126/Scitranslmed.Aal4682  0.467
2017 Gupta N, Badeaux M, Liu Y, Naxerova K, Sgroi D, Munn LL, Jain RK, Garkavtsev I. Stress granule-associated protein G3BP2 regulates breast tumor initiation. Proceedings of the National Academy of Sciences of the United States of America. PMID 28096337 DOI: 10.1073/Pnas.1525387114  0.513
2017 Liu H, Pinter M, Incio J, Lee H, Ho W, Crain J, Naxerova K, Di M, Jacobson A, Santos DD, Zanconato A, Deshpande V, Lillemoe K, Castillos CFd, Downes M, et al. Abstract 957: Use of angiotensin system inhibitors is associated with longer overall survival in pancreatic ductal adenocarcinoma patients who underwent pancreatectomy Cancer Research. 77: 957-957. DOI: 10.1158/1538-7445.Am2017-957  0.344
2017 Ferraro GB, Kodack DP, Askoxylakis V, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao AZ, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, et al. Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation Cancer Research. 77: 5008-5008. DOI: 10.1158/1538-7445.Am2017-5008  0.478
2016 Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig MK, Brachtel E, Duda DG, et al. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. Journal of the National Cancer Institute. 108. PMID 26547932 DOI: 10.1093/Jnci/Djv313  0.461
2015 Naxerova K, Elledge SJ. Taking the brakes off telomerase. Elife. 4. PMID 26194808 DOI: 10.7554/Elife.09519  0.304
2015 Naxerova K, Jain RK. Using tumour phylogenetics to identify the roots of metastasis in humans. Nature Reviews. Clinical Oncology. 12: 258-72. PMID 25601447 DOI: 10.1038/Nrclinonc.2014.238  0.443
2014 Naxerova K, Brachtel E, Salk JJ, Seese AM, Power K, Abbasi B, Snuderl M, Chiang S, Kasif S, Jain RK. Hypermutable DNA chronicles the evolution of human colon cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: E1889-98. PMID 24753616 DOI: 10.1073/Pnas.1400179111  0.477
2014 Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, et al. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Molecular Cancer Research : McR. 12: 754-64. PMID 24574516 DOI: 10.1158/1541-7786.Mcr-13-0532-T  0.431
2012 Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, Ancukiewicz M, Boucher Y, Jain RK, Xu L. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proceedings of the National Academy of Sciences of the United States of America. 109: 16618-23. PMID 22996328 DOI: 10.1073/Pnas.1117610109  0.638
2012 Helman E, Naxerova K, Kohane IS. DNA hypermethylation in lung cancer is targeted at differentiation- associated genes Oncogene. 31: 1181-1188. PMID 21804601 DOI: 10.1038/Onc.2011.307  0.313
2011 Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, Huang P, Kamoun W, Jain RK, Fukumura D, Xu L. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3638-48. PMID 21459800 DOI: 10.1158/1078-0432.Ccr-10-2456  0.489
2008 Naxerova K, Bult CJ, Peaston A, Fancher K, Knowles BB, Kasif S, Kohane IS. Analysis of gene expression in a developmental context emphasizes distinct biological leitmotifs in human cancers. Genome Biology. 9: R108. PMID 18611264 DOI: 10.1186/Gb-2008-9-7-R108  0.373
Show low-probability matches.